Several other equities analysts have also recently commented on the stock. Maxim Group restated a buy rating on shares of Cytosorbents Corp in a research report on Wednesday, June 15th. Brean Capital began coverage on shares of Cytosorbents Corp in a research report on Tuesday, October 4th. They issued a buy rating and a $24.00 target price for the company. Finally, B. Riley began coverage on shares of Cytosorbents Corp in a research report on Thursday, October 6th. They issued a buy rating and a $11.25 target price for the company. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus target price of $13.65.
Shares of Cytosorbents Corp (OTCMKTS:CTSO) opened at 5.55 on Tuesday. Cytosorbents Corp has a 1-year low of $3.11 and a 1-year high of $8.10. The company’s market capitalization is $141.18 million. The stock’s 50 day moving average is $5.81 and its 200 day moving average is $4.83.
Cytosorbents Corp (OTCMKTS:CTSO) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.03. The business had revenue of $1.90 million for the quarter, compared to analyst estimates of $2.18 million. On average, equities research analysts anticipate that Cytosorbents Corp will post ($0.39) EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock worth $2,447,000 after buying an additional 5,446 shares in the last quarter. Raymond James & Associates boosted its position in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock worth $1,477,000 after buying an additional 247,052 shares in the last quarter. Advisor Group Inc. bought a new position in Cytosorbents Corp during the second quarter worth about $1,372,000. Douglass Winthrop Advisors LLC bought a new position in Cytosorbents Corp during the second quarter worth about $321,000. Finally, BlackRock Fund Advisors boosted its position in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock worth $245,000 after buying an additional 15,203 shares in the last quarter.
About Cytosorbents Corp
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.